Posts

Do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)

ESMO 2023 | Dr. Naidoo reviews perioperative immunotherapy modalities for operable Non-Small Cell Lung Cancer

ESMO 2023 | Dr. McCormack analyzes the impact of the INTERLACE trial on the treatment of locally advanced cervical cancer

ESMO 2023 | Dr. Spicer explains controversies in perioperative immunotherapy for patients with early-stage NSCLC

ESMO 2023 | Dr. Lorusso commented on the results of the DUO-E and KEYNOTE-A18 trials

ESMO 2023 |Dr. Passaro reviews the exploration of the Amivantamab combination regimen in the treatment of EGFR-mutated NSCLC

ESMO 2023 |Dr. Girard analyses PAPILLON: Opening new doors for first-line treatment of EGFR Exon 20 insertion-mutated advanced NSCLC

ELCC 2023 | Expert Interview: The Role of Radiotherapy in the Treatment of Stage III Thymoma

ELCC 2023 | Chairman's Remarks: Dr. Reck Takes Stock of Important Oral Presentations at ELCC

ELCC 2023 | Researcher Interview: P. Garrido Lopez Interprets Latest Data from CHRYSALIS

ELCC 2023 | International Scholar Dr. Girard Deciphers Key Research Advances at ELCC

AACR 2023 | AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

SGBCC International Dialogue | Wang Jia & Professor William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis